FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2992704631> ?p ?o ?g. }

• W2992704631 endingPage "1105" @default.
• W2992704631 startingPage "1105" @default.
• W2992704631 abstract "Abstract In advanced BCR-ABL-positive leukemia, combination of chemotherapy with imatinib is expected to result in better reduction of leukemia cell load and may delay or offset clonal selection of resistant leukemia cells, thus improving the survival. We carried out a prospective phase I/II combination trial for patients (pts) with myeloid blast crisis of chronic myelogenous leukemia (CML). Pts were treated with imatinib+mitoxantrone/etoposide in four cohorts starting from mitoxantrone 10mg/m2/d and etoposide 100 mg/m2/d for 2 or 3 consecutive days and start of imatinib 600mg/d from day 15 (coh. 1 and 2) or from day 1 (coh. 3 and 4, respectively). After hematologic reconstitution following the cytopenic phase, cytarabine was administered at a dose of 10mg/m2/d s.c. in addition to imatinib as maintenance treatment. A total of 16 pts (8 m, 8 f) are available for analysis, median age 59 years (range 37–74). All pts who received more intensive induction treatment (coh. 3 and 4, n=7) achieved a hematologic response (HR). In contrast, HR was achieved in 6 of 9 pts treated in coh. 1 and 2. The induction treatment was well tolerated with a treatment-related mortality rate of 12.5% (1 intracranial hemorrhage in coh. 1, and 1 pneumonia in coh. 4). A median of 8 (2–18) red blood cell concentrates and a median of 5 (1–8) platelet concentrates were required. Antibiotic treatment for febrile episodes was administered for a median of 10d (0–38). Of note, CTC grade 3 or grade 4 mucositis did not occur. Pts who received imatinib on day 1 (coh. 3–4) had a longer duration of severe leukopenia (WBC &lt;1/nl) with a median of 19 days (0–23) vs. 2 (0–14) but without increase of infection incidence. Six pts who achieved HR received an allogeneic stem cell transplantation with myeloablative conditioning. Three of 6 transplanted patients are alive and in complete cytogenetic remission at 735, 723, and 279 days after initiation of study treatment. Two patients died of transplant-related complications (GvHD and sepsis), 1 patient died from hematologic relapse. Of 10 pts who received only conventional treatment, 1 (coh. 1) is still alive and in a complete cytogenetic remission at day 1280 after initiation of study treatment. Median survival of transplanted pts was 486 days, and 142 days in the group with conventional treatment only (p=0.078). We conclude that the combination of mitoxantrone/etoposide and imatinib is a well tolerated induction protocol with mild non-hematological toxicity even in older patients. Eligible pts have an advantage from an allogeneic stem cell transplantation following response to the induction treatment." @default.
• W2992704631 created "2019-12-13" @default.
• W2992704631 creator A5016147985 @default.
• W2992704631 creator A5020037857 @default.
• W2992704631 creator A5022515199 @default.
• W2992704631 creator A5029290022 @default.
• W2992704631 creator A5035964802 @default.
• W2992704631 creator A5058914292 @default.
• W2992704631 creator A5064625563 @default.
• W2992704631 creator A5067574718 @default.
• W2992704631 creator A5075280681 @default.
• W2992704631 creator A5078058786 @default.
• W2992704631 creator A5091140526 @default.
• W2992704631 date "2005-11-16" @default.
• W2992704631 modified "2023-10-06" @default.
• W2992704631 title "Combination Treatment with Imatinib and Mitoxantrone/Etoposide Is a Suitable Preparative Regimen before Allogeneic Transplantation in Patients with Myeloid Blast Crisis of Chronic Myeloid Leukemia." @default.
• W2992704631 doi "https://doi.org/10.1182/blood.v106.11.1105.1105" @default.
• W2992704631 hasPublicationYear "2005" @default.
• W2992704631 type Work @default.
• W2992704631 sameAs 2992704631 @default.
• W2992704631 citedByCount "0" @default.
• W2992704631 crossrefType "journal-article" @default.
• W2992704631 hasAuthorship W2992704631A5016147985 @default.
• W2992704631 hasAuthorship W2992704631A5020037857 @default.
• W2992704631 hasAuthorship W2992704631A5022515199 @default.
• W2992704631 hasAuthorship W2992704631A5029290022 @default.
• W2992704631 hasAuthorship W2992704631A5035964802 @default.
• W2992704631 hasAuthorship W2992704631A5058914292 @default.
• W2992704631 hasAuthorship W2992704631A5064625563 @default.
• W2992704631 hasAuthorship W2992704631A5067574718 @default.
• W2992704631 hasAuthorship W2992704631A5075280681 @default.
• W2992704631 hasAuthorship W2992704631A5078058786 @default.
• W2992704631 hasAuthorship W2992704631A5091140526 @default.
• W2992704631 hasConcept C126322002 @default.
• W2992704631 hasConcept C141071460 @default.
• W2992704631 hasConcept C143998085 @default.
• W2992704631 hasConcept C2776694085 @default.
• W2992704631 hasConcept C2776960273 @default.
• W2992704631 hasConcept C2777583451 @default.
• W2992704631 hasConcept C2778041864 @default.
• W2992704631 hasConcept C2778119113 @default.
• W2992704631 hasConcept C2778461978 @default.
• W2992704631 hasConcept C2778496288 @default.
• W2992704631 hasConcept C2778729363 @default.
• W2992704631 hasConcept C2780923524 @default.
• W2992704631 hasConcept C2911091166 @default.
• W2992704631 hasConcept C3019892230 @default.
• W2992704631 hasConcept C71924100 @default.
• W2992704631 hasConcept C90924648 @default.
• W2992704631 hasConceptScore W2992704631C126322002 @default.
• W2992704631 hasConceptScore W2992704631C141071460 @default.
• W2992704631 hasConceptScore W2992704631C143998085 @default.
• W2992704631 hasConceptScore W2992704631C2776694085 @default.
• W2992704631 hasConceptScore W2992704631C2776960273 @default.
• W2992704631 hasConceptScore W2992704631C2777583451 @default.
• W2992704631 hasConceptScore W2992704631C2778041864 @default.
• W2992704631 hasConceptScore W2992704631C2778119113 @default.
• W2992704631 hasConceptScore W2992704631C2778461978 @default.
• W2992704631 hasConceptScore W2992704631C2778496288 @default.
• W2992704631 hasConceptScore W2992704631C2778729363 @default.
• W2992704631 hasConceptScore W2992704631C2780923524 @default.
• W2992704631 hasConceptScore W2992704631C2911091166 @default.
• W2992704631 hasConceptScore W2992704631C3019892230 @default.
• W2992704631 hasConceptScore W2992704631C71924100 @default.
• W2992704631 hasConceptScore W2992704631C90924648 @default.
• W2992704631 hasIssue "11" @default.
• W2992704631 hasLocation W29927046311 @default.
• W2992704631 hasOpenAccess W2992704631 @default.
• W2992704631 hasPrimaryLocation W29927046311 @default.
• W2992704631 hasRelatedWork W1976396371 @default.
• W2992704631 hasRelatedWork W1986095564 @default.
• W2992704631 hasRelatedWork W1997103301 @default.
• W2992704631 hasRelatedWork W2023291141 @default.
• W2992704631 hasRelatedWork W2124201452 @default.
• W2992704631 hasRelatedWork W2133433269 @default.
• W2992704631 hasRelatedWork W2164450151 @default.
• W2992704631 hasRelatedWork W2245410905 @default.
• W2992704631 hasRelatedWork W2561219128 @default.
• W2992704631 hasRelatedWork W2992704631 @default.
• W2992704631 hasVolume "106" @default.
• W2992704631 isParatext "false" @default.
• W2992704631 isRetracted "false" @default.
• W2992704631 magId "2992704631" @default.
• W2992704631 workType "article" @default.